Exhibit 99.2 ™ Outsmarting Complex Diseases with Intelligent Medicines Corporate Overview December 2021

Disclaimer This presentation (“Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between Dynamics Special Purpose Corp. (“Dynamics”) and Senti Biosciences, Inc. (“Senti”) and a potential investment in connection therewith (the “Purpose”). By accepting this Presentation, the recipient acknowledges and agrees that all of the information contained herein is confidential, that the recipient will distribute, disclose, and use such information only for such Purpose and that the recipient shall not distribute, disclose or use such information in any way detrimental to Senti or Dynamics. The information contained herein does not purport to be all-inclusive and none of Dynamics, Senti, J.P. Morgan Securities LLC (“JPM”), Morgan Stanley & Co. LLC (“MS”) and BofA Securities, Inc. (“BofA”) nor any of their respective affiliates nor any of its or their controlling persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this Presentation, you confirm that you are not relying upon the information contained herein to make any decision. ANY SECURITIES TO BE OFFERED IN ANY TRANSACTION CONTEMPLATED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE OR FOREIGN SECURITIES LAW. ANY SECURITIES TO BE OFFERED IN ANY TRANSACTION CONTEMPLATED HEREBY HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES EXCHANGE COMMISSION (THE “SEC”), ANY STATE SECURITIES COMMISSION OR OTHER UNITED STATES OR FOREIGN REGULATORY AUTHORITY, AND WILL BE OFFERED AND SOLD SOLELY IN RELIANCE ON THE EXEMPTION FROM THE REGISTRATION REQUIREMENTS PROVIDED BY THE SECURITIES ACT AND RULES AND REGULATIONS PROMULGATED THEREUNDER (INCLUDING REGULATION D OR REGULATION S UNDER THE SECURITIES ACT). THIS PRESENTATION DOES NOT CONSTITUTE, OR FORM A PART OF, AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY IN ANY STATE OR OTHER JURISDICTION TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION IN SUCH STATE OR JURISDICTION. Certain statements in this Presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events or Dynamics’s or Senti’s future financial or operating performance. For example, statements concerning the following include forward-looking statements: Senti’s ability to identify, develop and commercialize product candidates; the initiation, cost, timing, progress and results of research and development activities, preclinical or clinical trials with respect Senti’s drug candidates; future revenue, expenses, capital requirements and needs for additional financing; and the potential effects of the Business Combination on Dynamics and Senti and related capital raising activities. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Dynamics and its management, and Senti and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including general economic conditions and other risks, uncertainties and factors set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Dynamics’s final prospectus relating to its initial public offering, dated May 25, 2021, and other filings with the SEC, as well as factors associated with companies, such as Senti, that are engaged in preclinical studies and other research and development activities in the biopharma industry, including uncertainty in the timing or results of preclinical studies and clinical trials, product acceptance and/or receipt of regulatory approvals for product candidates, including any delays and other impacts from the COVID-19 pandemic. Nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place any reliance on forward-looking statements in this Presentation, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Neither Dynamics nor Senti undertakes any duty to update these forward-looking statements. Certain information contained in this Presentation relates to or is based on studies, publications, surveys and Senti’s own internal estimates and research. In addition, all of the market data included in this Presentation involve a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while Senti believes its internal research is reliable, such research has not been verified by any independent source. This Presentation and any information communicated at any meetings related to your evaluation of the Business Combination are strictly confidential and should not be discussed outside your organization. Dynamics has retained JPM, MS and BofA as placement agents (together with their affiliates, partners, directors, agents, employees, representatives, and controlling persons, the “Placement Agents”) with respect to capital raising activities in connection with the Business Combination. The Placement Agents are acting solely as placement agents (and, for the avoidance of doubt, not as underwriters, initial purchasers, dealers or any other principal capacity) for Dynamics in connection with a potential transaction. The Placement Agents have not independently verified any of the information contained herein or any other information that has been or will be provided to you. Nothing contained herein or in any other oral or written information provided to you is, nor shall be relied upon as, a promise or representation of any kind by the Placement Agents, Dynamics or Senti, whether as to the past or the future. Without limitation of the foregoing, none of the Placement Agents, Dynamics or Senti shall be liable to you or any prospective investor or any other person for any information contained herein or that otherwise has been or will be provided to you, or any action heretofore or hereafter taken or omitted to be taken, in connection with this potential transaction. This presentation is being distributed solely for the consideration of sophisticated prospective purchasers who are institutional accredited investors with sufficient knowledge and experience in investment, financial and business matters and the capability to conduct their own due diligence investigation and evaluation in connection with the Purpose. This presentation does not purport to summarize all of the conditions, risks and other attributes of an investment in Dynamics or Senti. Information contained herein will be superseded by, and is qualified in its entirety by reference to, any other information that is made available to you in connection with the Purpose, including your investigation of Dynamics and Senti. Additional Information. In connection with the proposed Business Combination, Dynamics intends to file with the SEC a registration statement on Form S-4 containing a preliminary proxy statement/prospectus of Dynamics, and after the registration statement is declared effective, Dynamics will mail a definitive proxy statement/prospectus relating to the proposed Business Combination to its shareholders. This Presentation does not contain all the information that should be considered concerning the proposed Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination. Dynamics‘s shareholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed Business Combination, as these materials will contain important information about Senti, Dynamics and the Business Combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed Business Combination will be mailed to shareholders of Dynamics as of a record date to be established for voting on the proposed Business Combination. Dynamics shareholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to www.dspc.bio. Participants in the Solicitation. Dynamics and its directors and executive officers may be deemed participants in the solicitation of proxies from Dynamics ‘s shareholders with respect to the proposed Business Combination. A list of the names of those directors and executive officers and a description of their interests in Dynamics is contained in Dynamics’s final prospectus relating to its initial public offering, dated May 25, 2021, which was filed with the SEC and is available free of charge at the SEC’s web site at www.sec.gov, or by directing a request to www.dspc.bio. Additional information regarding the interests of such participants will be contained in the proxy statement/prospectus for the proposed Business Combination when available.

SENTI BIO Proprietary gene circuit technology platform enables the development of “smart” next-gen cell and gene therapies with enhanced efficacy, safety and control Multiple therapeutic modalities (e.g. NK cells, T cells, iPSCs, gene therapy, mRNA, etc.) offering vast opportunities Potential to address patients with high unmet needs in oncology, immunology, genetic diseases, neurology, cardiology, ophthalmology, and more Senti Bio designs gene circuits for next-gen cell Differentiated Allogeneic CAR-NK Oncology Pipeline and Collaborations and gene therapies with Spark (Roche) and BlueRock (Bayer) Allogeneic CAR-NK Anticipated IND filings in 2023 for product candidates SENTI-202 (AML) and SENTI-301 (HCC) Note: Acute Myeloid Leukemia (AML), Hepatocellular Carcinoma (HCC) 3

SENTI’S FOUNDING TEAM Senti is Founded and Led by Pioneers in Synthetic Biology and Cell Technologies FOUNDING TEAM Wilson Wong, Ph.D. Tim Lu, M.D., Ph.D. Philip Lee, Ph.D. Jim Collins, Ph.D. SCIENTIFIC ADVISOR CEO CTO SCIENTIFIC ADVISOR SENTI FOUNDERS’ AFFILIATIONS WORLD-CLASS COMPANY FOUNDERS REPRESENTATIVE PUBLICATIONS Genetic circuit design automation Alec A. K. Nielsen, Bryan S. Der, Jonghyeon Shin, Prashant Vaidyanathan, Vanya Paralanov, Elizabeth A. Strychalski, David Ross, Douglas Densmore and Christopher A. Voigt (March 31, 2016) Science 352 (6281), . [doi: 10.1126/science.aac7341] Editor's Summary Programming circuitry for synthetic biology 4 As synthetic biology techniques become more powerful, researchers are anticipating a future in which the design of biological circuits will be similar to the design of integrated circuits in electronics. Nielsen et al. describe what is essentially a programming language to design computational circuits in living cells. The circuits generated on plasmids expressed in Escherichia coli required careful insulation from their genetic context, but primarily functioned as specified. The circuits could, for example, regulate cellular functions in response to multiple environmental signals. Such a strategy can facilitate the development of more complex circuits by genetic engineering. Science, this issue p. 10.1126/science.aac7341 This copy is for your personal, non-commercial use only. Article Tools Visit the online version of this article to access the personalization and article tools: http://science.sciencemag.org/content/352/6281/aac7341 Obtain information about reproducing this article: Permissions http://www.sciencemag.org/about/permissions.dtl Science (print ISSN 0036-8075; online ISSN 1095-9203) is published weekly, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. Copyright 2016 by the American Association for the Advancement of Science; all rights reserved. The title Science is a registered trademark of AAAS. Downloaded from http://science.sciencemag.org/ on May 11, 2016

BIOLOGY’S CHALLENGES Today’s Cell and Gene Therapies Cannot Resolve Fundamental Disease Challenges …AND CANNOT OVERCOME FUNDAMENTAL CURRENT CELL AND GENE THERAPIES ARE SIMPLISTIC… DISEASE CHALLENGES Unable to precisely distinguish TARGET HETEROGENEITY diseased versus healthy cells CAR-NK CAR-T Unable to overcome multiple DISEASE EVASION disease mechanisms TIL iPSC Unable to be regulated after NARROW THERAPEUTIC WINDOW delivery into patients Gene mRNA Therapy Unable to adapt to disease DYNAMIC DISEASE CONDITIONS conditions 5

GENE CIRCUIT PLATFORM TECHNOLOGY Senti’s Gene Circuits Use Biological Computation to Solve Biological Problems Genetic Parts Gene Circuits Gene Networks Transcription factor Evolution has Evolution has selected for selected for natural natural genetic circuits. genetic circuits Target gene and binding site Adopted from Babu et. al. Curr Opin in Structural Bio, 14(3), 2004 CAR OR CAR NOT Logic Gate Gate Gating Senti creates intelligent Combo Calibrated Gene-Circuit Learning from Multi Effector Release Arming gene circuits. Enabled Cell and evolution, Senti Gene Circuit SM-regulated Gene Therapies creates intelligent Promoter Regulator gene circuits Dial Cell-type Cell-state Promoter Promoter Smart Sensor 6

SENTI’S DESIGN-BUILD-TEST-LEARN (DBTL) PROCESS Powerful and Scalable Engine Optimizes Gene Circuits to Enable Creation of Intelligent Medicines SENTI’S DESIGN-BUILD-TEST-LEARN ENGINE LEARN Central Knowledge Database Biological Data Optimized DESIGN BUILD TEST Gene Circuits Disease Indication Teams, in vivo Vector Core, Cell Manufacturing Centralized Gene Circuit Core, Disease Indication Teams Core, Analytical Core Design Team ▪ ML / computational algorithms▪ DNA, vector and cell engineering ▪ Automated high throughput screening ▪ Patient disease bioinformatics with GMP-relevant processes▪ Analytical testing on process efficiencies and robustness Hit Selection Alternative Designs Production Efficiency 7

SENTI’S GENE CIRCUIT SOLUTIONS Senti’s Gene Circuit Platform is Designed to Overcome Fundamental Disease Challenges FUNDAMENTAL DISEASE CHALLENGES… …ARE TACKLED THROUGH INTELLIGENT GENETIC PROGRAMMING Integrates multiple targets to pinpoint diseased cells and spare TARGET HETEROGENEITY LOGIC GATING healthy ones Targets multiple disease pathways DISEASE EVASION MULTI-ARMING within a single all-in-one drug Dynamically regulates therapies in NARROW THERAPEUTIC WINDOW REGULATOR DIAL vivo using FDA-approved oral drugs Precisely detects and responds to DYNAMIC DISEASE CONDITIONS SMART SENSOR disease environments 8

WE BELIEVE THAT OUR GENE CIRCUITS SOFTWARE PLATFORM IS BROADLY APPLICABLE Gene Circuits Could Potentially Power Multiple Cell and Gene Therapy Modalities for Broad Therapeutic Potential Diverse Modalities CAR OR CAR NOT Logic Gate Gate Gating NK Cells T Cells AAVs Combo Calibrated Multi Effector Release Arming Gene HSCs iPSCs Circuit SM-regulated Promoter Regulator Indications Dial • Oncology • Cardiology Cell-type Cell-state• Immunology • Ophthalmology Promoter Promoter Smart • Genetic Diseases • Neuro Sensor • Metabolic Diseases 9

SENTI’S GENE CIRCUITS Logic Gating Enables Highly Specific Therapies by Recognizing Multiple Antigens Toolbox of TUMOR-ASSOCIATED ANTIGENS (TAA) SAFETY ANTIGEN ENGAGEMENT Gene Circuits ENGAGEMENT TRIGGERS CANCER CELL KILLING ENABLES PROTECTION OF HEALTHY CELLS SENTI NOT-GATE CANCER CELL SENTI NOT-GATE HEALTHY Logic Gating CAR-NK CELLS CAR-NK CELLS CELL Multi Arming Regulator Dial Smart Sensor Activating CAR (aCAR) Tumor-Associated Antigens Inhibitory CAR (iCAR) Safety Antigen 10

SENTI’S GENE CIRCUITS NOT Logic Gate Functions In Vivo to Specifically Kill Cancer Cells and Spare Healthy Cells Toolbox of NOT-GATED CAR-NK CELLS REDUCE RESULTING IN ENRICHMENT Gene Circuits NOT-Logic-Gated Healthy Cancer 50:50 KILLING OF HEALTHY CELLS OF HEALTHY CELLS CAR-NK Cells Cells Cells Cancer Cells Healthy Cells ** Logic + 70 + **** Gating 60 50 40 Multi Arming I.V. injection 30 20 10 Regulator Blood collection Dial 0 NOT GATE NOT GATE Control CAR- Control Control CAR-NK NOT GATE CAR-NK Healthy Cells Cancer Cells NK Cells CAR-NK Cells CAR-NK CAR-NK Cells Cells Spared Killed Cells Cells Smart Sensor Source: Internal data 11 % of All Blood Cells

SENTI’S GENE CIRCUITS Multi-Arming Circuits Enable All-in-One Combination Cell and Gene Therapies Toolbox of Multiple Immune Gene Circuits Stimulators: Central Knowledge LEARN Database Logic IL15 Gating IL21 IL7 Biological Data IL18 Multi Optimized Arming IL12 Gene DESIGN BUILD TEST Circuits [….] Disease Indication Centralized Gene Vector Core, Cell Circuit Design Team Manufacturing Core, Teams, in vivo Core, Regulator Analytical Core Disease Indication Teams Dial Use of Senti’s Design-Build-Test-Learn Engine optimizes each payload’s expression level and which combinations are expressed from Multi-Arming gene circuits to enhance therapeutic activity Smart Sensor 12

SENTI’S GENE CIRCUITS Multi-Armed CAR-NK Cells Exhibit Significantly Improved Killing of Cancer Cells TUMOR CELL KILLING Toolbox of IN VITRO TUMOR CELL KILLING (INCUCYTE) (day 5 post co-culture, 2:1 ratio) Gene Circuits Tumor cells alone CAR-NK (no cytokines) CAR-NK + cytokine 1 CAR-NK + cytokine 2 Tumor cells alone CAR NK Tumor cells CAR NK SENTI CAR-NK + cytokine 1+2 Tumor cells CAR-NK alone Logic 100 alone Gating 80 60 Multi Arming CAR-NK + SENTI CAR-NK + 40 cytokine 1 cytokine 1+2 CAR NK CAR NK CAR NK + cytokine 1+2 + cytokine 1 + cytokine 1+2 20 Regulator Dial 0 Red fluorescence = tumor cells 0 40 60 80 100 120 Elapsed time (hours) Smart Sensor Arming of CAR-NK cells using a combination of cytokines results in potent and durable killing Source: Internal data 13 Relative Tumor Cell Abundance (%)

SENTI’S GENE CIRCUITS Regulator Dial Circuit Potentially Enables Control of Cell Therapies Using FDA- Approved Drugs Toolbox of OFF MULTIPLE DRUG ON Gene Circuits SWITCHES: Logic • HCV protease inhibitors Gating • IMiDs Little/no immune Multi • Tamoxifen Arming effectors secreted in absence of small molecule drug Regulator Dial Cytokine payload is expressed only in presence of small molecule drug Smart Sensor 14

SENTI’S GENE CIRCUITS Regulator Dial Enables ~90-fold ON/OFF Control of IL-12 Secretion In Vivo STUDY DESIGN Toolbox of Immune deficient NSG mice Gene Circuits ± Logic GRZ 75 mg/kg Vehicle or dGR oseZ Dosed dose No Vehicle or GRZ Dosed 1/2 dose dose dose Gating or vehicle Day -2 -1 0 1 2 3 4 8 Randomization Cell injection Collect plasma Collect plasma Multi Arming IL-12 DETECTED IN MOUSE PLASMA 10,000 Vehicle *** GRZ 75mg/kg Regulator Dial 1,000 ns 100 Smart Sensor 10 Day 4 Day 8 *** p < 0.001 Source: Internal data 15 IL-12 (pg/mL)

SENTI’S GENE CIRCUITS Smart Sensors Enable Precise and Dynamic Recognition of Diseased Cells Toolbox of CURRENT GENE THERAPIES LACK SPECIFICITY FOR SPECIFIC DISEASED CELL TYPES Gene Circuits ON-target cells OFF-target cells Logic Gating Differential transcription factor profiles between cell types Multi Arming Active No activity TF binding response sites Combinatorial Libraries Regulator Dial Top performing circuit Smart Sensor v1.1 v1.2 v1.3 16

SENTI’S GENE CIRCUITS Smart Sensor Promoters Enable up to 1,000-fold Selectivity for Diseased Cells SIGNALS SUCH AS GENE THERAPY WITH TRANSGENE EXPRESSION Toolbox of TRANSCRIPTION FACTOR(S) UP TO ~1,000X CELL TYPE SELECTIVITY Gene Circuits Logic Gating 100,000x * * 10,000x Multi 1,000x Arming 100x 10x Cancer-specific Regulator Dial transcription factor(s) 1x Cancer Cell Synthetic Promoter Healthy Cell Synthetic Promoter Cell Line: Healthy Breast * p < 0.05 Breast Cancer Smart Sensor Source: Wu et al. Nature Communications 10, Article number 2880 (2019) 17 Median Fluorescence Intensity

PIPELINE Gene Circuit Enabled Pipeline With Additional Collaboration Opportunities Modality Gene Circuit Name Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Rights Acute Myeloid SENTI-202 Leukemia SENTI-401 Colorectal Cancer Logic Gating SENTI-411 Solid Tumors Allogeneic SENTI-421 Solid/Liquid Tumors NK Cells for Hepatocellular SENTI-301 Oncology Multi- Carcinoma Arming SENTI-311 Solid Tumors GC-1001 Ocular /-1002 Smart GC-1003 Central Nervous Gene Therapies /-1004 System Sensor for Tissue- GC-1005 Liver Directed Targets Regenerative GC-1101 Regulator Medicine Regenerative Dial GC-1102 Cell Therapies Medicine for Regenerative Smart Regenerative GC-1103 Medicine Medicine Sensor Note: Spark is a wholly owned subsidiary of Roche; Bluerock is a wholly owned subsidiary of Bayer 18 For further details regarding the Spark and BlueRock collaborations, please see page 33 and 34

WHY NK CELLS? Natural Killer (NK) Cells are an Ideal Modality for Gene-Circuit Enhanced Cancer Cell Therapy Innate Killing Immune Activation Favorable Safety Broad Access Clinical Validation ü Natural ability to ü Proinflammatory ü Low/no incidence ü Does not require ü MD Anderson CD19 kill tumor cells and cytokine and of GvHD vs. CAR-T patient derived CAR-NK study in spare healthy ones chemokine cells advanced B cell based on multi- secretion malignancies: 7/11 ü Low risk of CRS receptor (64%) CRs and no and neurotoxicityü Potential for engagement reported CRS, GvHD ü Elicit endogenous outpatient or neurotoxicity response for administration ü Anti-tumor activity durable anti-tumor and persistence immunityü Fate Therapeutics ü Amenable to validated study with FT516 in large scale B-cell lymphoma: allogeneic 6/11 (55%) CRs and manufacturing no CRS, GvHD or neurotoxicity 19 Note: MD Anderson study data was presented at ASH 2020 and Fate Therapeutics study was presented on August 19, 2021

PROPRIETARY CALIBRATED RELEASE IL-15 Senti’s Proprietary Calibrated Release IL-15 (crIL-15) Enhances NK Cell Persistence and Tumor Killing crIL-15 ENABLES BOTH AUTOCRINE AND PARACRINE SIGNALING crIL-15 IMPROVES NK PERSISTENCE AND SERIAL KILLING Tumor cells alone Unengineered NK cells Un-engineered NKs Unengineered NK Cells SENTI CAR-NK + crIL-15 CAR-NK + wtIL-15 5 4 CAR-NK + wtIL-15 3 2 **** **** 1 SENTI CAR-NK + crIL-15 crIL-15 SENTI CAR-NK + crIL-15 ns 0 0 24 48 72 96 120 144 168 192 Hours Red fluorescence = tumor cells ns = not significant; **** p= <0.0001 rd Images taken from 3 round 20 Source: Internal data Relative Tumor Cell Abundance

SENTI-202: LOGIC-GATED CAR-NK CELLS FOR PRECISION TARGETING OF AML SENTI-202: Designed to Address Unmet Needs in the Treatment of Acute Myeloid Leukemia (AML) Toolbox of SENTI’S LOGIC GATES SOLVE KEY DISEASE CHALLENGES IN AML UNMET NEED IN AML Gene Circuits CHALLENGES SENTI GENE CIRCUIT SOLUTIONS 1 5-Year Survival Logic OR Logic Gate Target heterogeneity Gating Relapse due to incomplete Targets multiple AML tumor associated antigens targeting of leukemic stem cells (LSCs) 29.5% Multi Arming Target heterogeneity NOT Logic Gate Off-tumor toxicity and limited Enables broad targeting of AML while preserving healthy blood efficacy due to lack of AML- Regulator DUE TO DISEASE RELAPSE stem cells specific targets Dial DRIVEN BY LEUKEMIC STEM CELLS (LSCs) SENTI’S LOGIC-GATED CAR-NK PROGRAM OFFERS POTENTIAL TO DEVELOP A CURE FOR AML PATIENTS Smart IN THE ABSENCE OF A BONE MARROW TRANSPLANT Sensor 1 SEER Cancer Stat Facts: Acute Myeloid Leukemia 21

SENTI-202 SUMMARY SENTI-202: Potential to Develop a Cure With No Bone Marrow Transplant Needed PRODUCT SCHEMATIC FLT3 OR CD33 EMCN CAR OR CAR NOT Logic aCAR iCAR Gate Gate Gating Combo Calibrated Multi Effector Release crIL-15 Arming Gene Circuit SM-regulated Promoter Regulator Dial Cell-type Cell-state Promoter Promoter Smart Sensor Allogeneic SENTI OR+NOT- Gate CAR-NK Cells 22

SENTI-202 OR/NOT LOGIC GATING SENTI-202 OR/NOT Logic Gating: Deep Clearance of AML Blasts and AML LSCs While Sparing Healthy Hematopoietic Stem Cells (HSCs) FLT3 OR CD33 ENGAGEMENT TRIGGERS EMCN ENGAGEMENT ENABLES KILLING OF HETEROGENEOUS AML CANCER CELLS PROTECTION OF HEALTHY HSCs SENTI-202 CAR- AML CANCER SENTI-202 CAR- HEALTHY NK CELL CELLS NK CELL HSC Protecting 10-20% of HSCs May Be Clinically Meaningful Activating CAR (aCAR) Tumor-Associated Antigens Inhibitory CAR (iCAR) Safety Antigen Antigen: CD33 FLT3 EMCN 23

OR GATE: CAR-MEDIATED NK CELL KILLING FLT3 OR CD33 CAR-NK Cells Significantly Suppressed Tumor Growth, Reduced Tumor Burden and Improved Survival Day 30 p-values MV4-11-BASED AML Moderate Significant No Cancer (3) vs (2): p < 0.05 XENOTRANSPLANTATION MODEL Tumor Load Tumor Load (3) vs (1): p < 0.01 Untreated (1) Unengineered NK Cells (2) Groups SENTI OR Gate CAR-NK (3) 1 100 Untreated 75 2 Unengineered NK cells 50 P-Values (3) vs (1): p < 0.01 3 (3) vs (2): p < 0.01 25 SENTI OR Gate (2) vs (1): p < 0.01 CAR-NK 0 0 20 40 60 80 DAY 9 13 20 30 Time (days) FLT3 OR CD33 CAR-NK cells significantly suppressed tumor growth and increased survival SENTI FLT3 OR CD33 CAR-NK cells achieved statistically significantly greater anti-tumor activity compared to untreated control mice (p < 0.01) and mice treated with unengineered NK cells (p < 0.05) 24 Source: Internal data Percent survival

NOT GATE DISCRIMINATION STUDY: FLT3 CANCEROUS CELLS VS EMCN+ HEALTHY CELLS EMCN iCAR Constructs Demonstrate Functional NOT GATE Protection of Model Healthy Cells KEY TAKEAWAYS CAR-NK cells without an EMCN- specific NOT GATE kill both FLT3+ 1:2 (E:T) ratio; 18hrs FLT3+ FLT3+ EMCN+ and FLT3+EMCN+ cells. 60 ns ** *** 50 CAR-NK cells containing an EMCN-specific NOT Gate protect 40 50% up to 67% of EMCN-expressing protection 67% target cells while preserving protection 30 effective CAR-NK-cell-mediated killing of FLT3+ cancer cells. 20 We believe that protecting 10- 10 20% of Healthy HSCs is clinically 0 meaningful. aCAR FLT3+, aCAR FLT3+, aCAR FLT3+, Non-Specific NOT GATE EMCN iCAR v1 EMCN iCAR v2 NK Cells Source: Internal data 25 Note: ns = not significant; ** p < 0.01, *** p < 0.001 Percent of CAR-NK Cell-Mediated Killing

NOT GATE DISCRIMINATION STUDY: AML CANCER CELLS VS PRIMARY HEALTHY BLOOD STEM CELLS SENTI-202 Product Candidate Protects Primary Donor HSCs While Maintaining On- Target Killing of Cancer Cells EMCN NOT-GATE CAR-NK CELLS EFFECTIVELY KILL EMCN NOT-GATE CAR-NK CELLS PROTECT AML CANCER CELLS HEALTHY HSCs/MPPs 60 ** 100 90 50 80 40 47% 70 protection 60 30 50 40 20 30 10 20 10 0 FLT3 OR CD33 CAR-NK FLT3 OR CD33 NOT EMCN FLT3 OR CD33 CAR-NK FLT3 OR CD33 NOT Cells CAR-NK Cells Cells EMCN CAR-NK Cells Experimental Approach: OR GATE OR+NOT GATE Healthy OR+NOT GATE OR GATE Healthy AML Cell AML Cell CAR-NK Cell CAR-NK Cell HSC/MPP CAR-NK Cell CAR-NK Cell HSC/MPP We believe that protecting 10-20% of Healthy HSCs is clinically meaningful. Source: Internal data 26 % Killing HSC/MPP CAR-Mediated Killing (%)

SENTI-301: CAR-NK CELLS WITH MULTI ARMING AND REGULATOR DIAL CIRCUITS FOR ENHANCED TREATMENT OF HCC SENTI-301: Addressing Unmet Needs in the Treatment of Hepatocellular Carcinoma (HCC) SENTI’S MULTI-ARMING AND REGULATOR DIAL Toolbox of GENE CIRCUITS SOLVE KEY DISEASE CHALLENGES IN HCC UNMET NEED IN HCC Gene Circuits CHALLENGES SENTI GENE CIRCUIT SOLUTIONS Logic Sixth most Gating Disease evasion Multi Arming commonly Targets multiple pathways with Suppressive tumor diagnosed microenvironment (TME) potent immuno-stimulators to cancer globally overcome TME limits efficacy Multi Diseased liver Arming Narrow therapeutic window Regulator Dial Death rate Immuno-stimulators to Enables exogenous switching of increasing in potent immuno-stimulators Regulator overcome TME need to be the U.S. from Dial controlled 2000-2016 Smart SENTI’S CAR-NK CELLS WITH MULTI-ARMING AND REGULATORY DIAL GENE CIRCUITS HAVE THE POTENTIAL TO Sensor OVERCOME SOLID TUMOR BARRIERS FOR HCC PATIENTS 27 Source: Villanueva, 2019 HCC review

SENTI-301 SUMMARY SENTI-301 Aims to Safely Overcome the Immunosuppressive Tumor Micro-Environment for Patients with R/R HCC PRODUCT SCHEMATIC GPC3 CAR-NK + Regulated, Multi Arming CAR OR CAR NOT Logic Regulated Gate Gate Gating Payload IL-12 Expression for Safety & Control Combo Calibrated Multi Effector Release Arming Gene Circuit SM-regulated Promoter Regulator crIL-15 Dial Cell-type Cell-state Promoter Promoter Smart Sensor Allogeneic SENTI Regulated, Multi-Armed CAR-NK Cells 28

SENTI-301: ADDRESSING UNMET NEEDS WITH REGULATED, MULTI-ARMING GENE CIRCUIT SENTI-301 Multi-Arming Approach is Designed to Attack Cancer in Multiple Complementary Ways IMPROVE CAR-NK PERSISTENCE AND EFFECTOR FUNCTIONS WITH OPTIMIZED IMMUNE CELL RECRUITMENT AND DIRECT KILLING crIL-15 SIGNALING TUMOR KILLING SENTI-301 CAR-NK CELL SENTI-301 CAR-NK CELL IL-12 ÌÌ GPC3 CAR Attack crIL-15 SENTI-301 HCC CANCER CELL CAR-NK CELL 29

SENTI-301: ADDRESSING UNMET NEEDS WITH REGULATED, MULTI-ARMING GENE CIRCUIT SENTI-301 Cancer Killing Demonstrates Multi-Arming and Regulator Dial Approaches Confirmed with Preclinical Studies IMPROVE CAR-NK PERSISTENCE AND EFFECTOR FUNCTIONS WITH OPTIMIZED IMMUNE CELL RECRUITMENT AND DIRECT KILLING crIL-15 SIGNALING TUMOR KILLING GPC3+ CANCER CELL KILLING crIL-15 ARMING REGULATED IL-12 ARMING Tumor cells alone crIL-15 secreted per 5 1 1 Unengineered NK cells crIL-15 on cell surface 1e6 cells (pg/ml) C C min max 1,000 SENTI CAR-NK + crIL-15 140 4 120 100 3 100 ÌÌ 2 80 10 60 1 1 0 Unengineered NK cells 0 0.001 0.01 0.1 1 0 1 2 3 SENTI CAR-NK + crIL-15 Days GRZ (uM) Source: Internal data 30 ¹ Serum Cmin and Cmax of GRZ in human Relative Tumor Cell Abundance IL-12 Secretion (pg/mL)

CAR-NK MANUFACTURING Senti’s Allogeneic Manufacturing Designed to Enable Widespread Distribution Senti Anticipates Scalable ~21 Day Process to Manufacture NK Cell Product With Off-the-Shelf Availability for Patients 1 2 3 4 5 6 Starting Cells Gene Modification Expansion Freezing & Prescription Infusion Distribution Patient receives prescription crIL-15 CAR-NK CELLS PURIFIED NK CELLS Lentiv VECTORS irus >100 DOSES PER EXPANDED CAR- BATCH NK CELLS Product arrives and is PATIENT HEALTHY DONOR thawed at clinic High purity and functional NK cells Vectors optimized for Proprietary expansion and Patient requests a Patient receives isolated from peripheral blood NK cell transduction cryopreservation process for >100 prescription from “Off-the-shelf” infusion doses per batch and high post-thaw physician at a clinical site potency 31

NK MANUFACTURING Strategy to Build, Control, and Scale In-House GMP Allogeneic Cell Manufacturing Pivotal/Commercial Clinical Expansion of manufacturing Flexible cell facility for GMP manufacturing, product testing, and Development therapy suites to commercial support Phase 1/2 storage (~92,000 sf) - Alameda, CA capacity and larger clinical trials in a Innovative process scales dedicated cGMP and analytical manufacturing development labs facility in a R&D facility 2018 2022 2025 Key Takeaways • Senti plans to operate in-house facilities and develop proprietary processes for manufacturing and testing of CAR-NK cell therapies Multi-modal preclinical research labs (~40,000 • Industry-leading contract manufacturing and testing partners leveraged sf) - South San Francisco, CA for standardized components 32 Manufacturing Scale Clinical / Pivotal / Commercial Development

MANUFACTURING COLLABORATION Senti May Seek to Leverage its GMP Facility to Expand Synthetic Biology Enabled Biomanufacturing Through a Partnership ILLUSTRATIVE BIOMANUFACTURING DEAL STRUCTURE Senti Gets: Therapeutic Applications o Operational control of part of the GMP facility for its use o Expansion of Gene Circuits to biomanufacturing applications Gene Circuit IP o Operational and financial support from Partner + GMP Facility Partner Gets: o Ability to operate part of the GMP facility for Partner contract manufacturing o License to Gene Circuit IP only for use in Bio-Manufacturing Applications biomanufacturing o Services Agreement with Senti 33

CURRENT CELL THERAPIES INADEQUATELY ADDRESS FUNDAMENTAL CHALLENGES IN CANCER Today’s Cell Therapies Cannot Resolve Key Cancer Challenges CURRENT AUTO CURRENT ALLO SENTI’S GENE CIRCUIT CURRENT ALLO CAPABILITIES T CELLS NK CELLS ENHANCED ALLO NK CELLS T CELLS POTENTIAL FOR OFF-THE-SHELF ADMINISTRATION WITH BROAD PATIENT ûüüü ACCESSIBILITY ENGINEERED WITH AUTOCRINE & PARACRINE SIGNALING FOR ENHANCED ACTIVITYûûûü DESIGNED WITH LOGIC GATES TO ACHIEVE – + / ENHANCED SPECIFICITYûûü ARMED WITH MULTIPLE MODES OF ACTION TO – + – + – + / / / IMPROVE EFFICACYü ENABLES CONTROL AND REGULATION OF – + / PRODUCT AFTER TREATMENTûûü 34

SPARK COLLABORATION Spark Therapeutics Collaboration Will Leverage Smart Sensor Gene Circuit Technology to Develop Potential Next-Generation Precision Gene Therapies ILLUSTRATIVE PRODUCT SCHEMATIC DEAL SUMMARY AAV Gene Therapy with Cell Type-Specific Smart Sensor o Collaboration & option: Senti will design, build and test cell-specific and disease- specific Smart Sensor synthetic AAV promoters for use in Spark’s next-gen Capsid Senti Synthetic Promoter Therapeutic Payload gene therapy products, with Spark having the option to exclusively license such promoters Low payload High payload expression in OFF expression in ON o Field: Certain indications pertaining to Target cell type(s) Target cell type CNS-, eye- or liver-targeted gene therapy products Synthetic Promoter Performance Profile: o Economics: Aggregate potential value of upfront, opt-in, development, regulatory and sales milestone payments may Compact promoter size to accommodate therapeutic exceed $645M, not including research payload transgene within ~4.5 kb AAV vector funding and royalties on a per product basis *Spark collaboration announced April 2021 35

BLUEROCK COLLABORATION Senti Entered Into a Collaboration with BlueRock Therapeutics to Develop Potential Next-Generation Regenerative Medicines ILLUSTRATIVE PRODUCT SCHEMATIC DEAL SUMMARY Gene Circuit-Engineered “Smart” Regenerative Medicines = Collaboration & Option: Senti will design, build, and test cell state- and Example Gene Circuits disease- specific Smart Sensors and Regulator Dials for use in BlueRock Senti Synthetic iPSC-derived Therapeutics’ regenerative medicine Promoter Therapeutic cell therapy product candidates, with BlueRock Disease-Specific 1 Payload having the option to negotiate and Smart Sensor enter into an exclusive or non- exclusive license in respect of such Smart Sensors and Regulator Dials Oral drug ON OFF = Field: Specified indications including Regulator + but not limited to neurology, 2 Dial Therapeutic cardiology and immunology within Payload the field of regenerative medicine, depending on the gene circuit and cell types = Economics: Not disclosed *BlueRock collaboration announced May 2021 36

USE OF PROCEEDS Over $290mm of Gross Proceeds in Combined SPAC and PIPE Financing Multiple Key Milestones Expected to be Achievable Into 2025 Pro Forma Cash of $326M Provides Runway o Present SENTI-301, SENTI-202, and SENTI-401 IND-enabling Into 2025 pharmacological data at key scientific conferences (AACR, ASGCT, SITC or equivalent) 3 SPAC Cash in Trust $230.0 o Complete first stage of construction for clinical-scale GMP facility PIPE Capital 66.8 1,2,4 Cash from Target Balance Sheet 50.0 o File INDs for SENTI-202, SENTI-301, and SENTI-401 5 Cash from SPAC Working Capital 0.5 o Pre-clinical POC for additional CAR-NK pipeline programs 6 Illustrative Fees & Expenses (21.7) o Clinical POC for SENTI-301 Estimated pro-forma cash $325.6 o Clinical POC for SENTI-202 1 2 No debt, no warrants; 2019, 2020 PCAOB audits completed to date, and quarterly 3 4 reviews in 2021 by KPMG; Assumes no redemptions from SPAC trust; Based on o First patient dosed for SENTI-401 5 projected cash balances of the Target as of December 31, 2021; Based on projected cash balance of the SPAC held outside of the trust account as of December 31, 2021; 6 Includes an estimate of fees from the M&A and PIPE transactions, deferred o Initiate final stage of construction for commercial-scale manufacturing underwriting fees and legal and accounting costs facility o File approximately one additional IND per year after the above three programs 37

PROGRESS & UPCOMING MILESTONES YTD Progress Sets The Stage For Upcoming Value Driving Milestones 2021 YTD Achievements Anticipated 2022 Milestones Anticipated 2023 Milestones Data readouts: Present SENTI-301 and SENTI-202 IND-enabling File INDs for SENTI-301 and Presented pre-clinical POC data at AACR, pharmacological data at key scientific conferences SENTI-202 demonstrating proprietary antigen discovery platform (AACR, ASGCT, SITC or equivalent) Present SENTI-401 IND-enabling and NOT Logic Gate functionality pharmacological data at key scientific conferences (AACR, Presented preclinical data at ASGCT for SENTI-202 and Pre-IND meetings for SENTI-301 and SENTI-202 ASGCT, SITC or equivalent) SENTI-301 o SENTI-202: Demonstrated AML antigen-specific OR Pre-IND meeting for SENTI-401 Gate and NOT Gate efficacies Apply for Orphan Drug Designation for SENTI-301 o SENTI-301: Demonstrated use of Regulator Dial and SENTI-202 Pre-clinical POCs for additional gene circuit for in vivo control of IL-12 expression pipeline candidates Manufacturing: Initiate preclinical work on additional CAR-NK Present further platform pipeline programs ISCT and CAR-TCR Summit presentations validating data in gene therapy demonstrating a GMP relevant allogeneic CAR-NK process Complete first stage of construction for clinical-scale GMP facility Business development and financial: Anticipated 2024+ Signed collaborations with Spark and BlueRock Present clinical-scale GMP manufacturing process for gene-circuit-engineered NK cells at key technical Raised $105mm Series B round conferences Approximately one IND per year 38

MANAGEMENT TEAM Industry-leading Management with Top-tier Board, Scientific Advisors and Investors 1 EXECUTIVE TEAM Tim Lu, M.D., Ph.D. Philip Lee, Ph.D. Jose Iglesias, M.D. Curt Herberts, M.B.S. Deb Knobelman, Ph.D. CTO & CO-FOUNDER CEO & CO-FOUNDER CHIEF MEDICAL ADVISOR COO CFO BOARD OF DIRECTORS SCIENTIFIC ADVISORS SELECT INVESTORS Jim Collins, Ph.D (Chair) MIT Susan Berland Senior Financial Executive Lee Cooper, J.D., MBA Michael Andreeff, M.D., Ph.D. MD Anderson Cancer Center LEAPS by Bayer Brenda Cooperstone, M.D. Lawrence Fong, Ph.D. Pfizer Rare Disease UCSF Martin Fussenegger, Ph.D. ~$158mm Ran Geng Matrix (OrbiMed) ETH Zurich in capital raised Michael Kalos, Ph.D. Alex Kolicich Arsenal, Janssen, Lilly 8VC to-date Ed Mathers NEA Ahmad (Mo) Khalil, Ph.D Boston University Tim Lu M.D., Ph.D. Robin Taylor, Ph.D., MBA SeaGen, Genentech CEO & Co-Founder Michael Varney, Ph.D. Erasca, Genentech Wilson Wong, Ph.D. Boston University 1 39 Note: Gary Lee, who has served as our Chief Scientific Officer since October 2018, has informed us that he intends to leave the Company in the first quarter of 2022

SPAC TEAM Dynamics is Led by an Experienced Team with a Track Record of Success Executive Experience Background o Founder, Chair, and CEO of Seer in 2017, advancing a transformative proteomics platform Omid Farokhzad o Previously co-founded Selecta Biosciences, Tarveda Therapeutics, and BIND Therapeutics (acquired by Pfizer) Executive Chair o Previously CTO at Illumina (2008-2021), and co-founded GRAIL and the Illumina Accelerator Program Mostafa Ronaghi o Currently serves as a Board Member for Seer, 1Health and Clearlabs Chief Executive Officer o Previously partner at Silver Rock Financial, (~$3bn AUM), covering healthcare from 2010-2021 Mark Afrasiabi o High-Yield Research Analyst and Portfolio Manager at PIMCO prior to joining Silver Rock Chief Financial Officer Rowan Chapman o Currently serves as an independent director at Evidation Health and Natera Chief Business Officer o Previously regional Head of Johnson & Johnson Innovation and global Head of Healthcare Investing at GE David Epstein o Serves as Chair of Rubius, Evelo and Axcella, and Executive Partner at Flagship Independent Director o From 2010 to mid-2016, served as CEO of Novartis Pharmaceuticals (division of Novartis) o Led Illumina as CEO from 1999 to 2016 before serving as Executive Chair and later Chair of the Board Jay Flatley o Currently serves on the Board of Directors of Coherent and Denali Therapeutics Independent Director o Currently Senior Managing Partner of the Softbank Vision Fund; serves on Boards of Seer, Relay and Vir Deep Nishar Independent Director o Previously an executive at LinkedIn and Google o David H. Koch Institute Professor at MIT and co-founded more than 30 companies, including Moderna Robert Langer o Received over 220 major awards and is one of 5 living individuals to have received both the United States Chief Scientific Advisor National Medal of Science (2006) and the United States National Medal of Technology and Innovation (2011) 40

TRANSACTION OVERVIEW A Compelling Transaction for All Stakeholders → Exposure to new class of biotech with a novel modality-agnostic drug development platform backed by groundbreaking science → SPAC + PIPE firepower enables multi-year runway through clinical POC 1 Sources and Uses ($mm) Pro-forma Valuation $mm, except per share data Sources 2 SPAC Cash in Trust $230.0 Share price $10.00 PIPE Capital 66.8 Pro-forma shares outstanding 60.1 3 Cash from Target Balance Sheet 50.0 Negotiated Pro-forma Equity Value $601 4 Cash from SPAC Working Capital 0.5 (+) Standalone debt 5 Target Rollover Equity 240.0 (-) Cash to BS / Primary Proceeds (326) Total Sources $587.3 Pro-forma Enterprise Value $276 Uses Target Rollover Equity $240.0 7 Illustrative Pro-forma Ownership Cash to BS / Primary Proceeds 325.6 Assumes $10.00 share price 6 Illustrative Fees & Expenses 21.7 1% 8% Total Uses $587.3 5 Existing Target Holders 11% Additional Transaction Details 8 40% SPAC Public → 100% rollover by target equity holders → Pro-forma equity value of $601mm and enterprise value of $276mm PIPE Investors → Incremental Target equity holder earn-out of 2mm shares 9 Founder Shares → $86.9mm of the SPAC trust committed to non-redemption agreements → $66.8mm fully committed PIPE 40% SPAC Private Placement Shares → Transaction expected to close in Q2 of 2022, subject to customary closing conditions 1 2 3 4 Assumes no redemptions and net of estimated transaction expenses; Assumes no SPAC trust redemptions; Based on projected cash balances of the Target as of December 31, 2021; Based on projected cash balance of the SPAC held outside of the trust account as 5 6 of December 31 2021; Includes all holders of outstanding convertible notes and outstanding equity awards of the Target, whether vested or unvested, on an as-converted or net exercise basis at $10/share exercise price, as applicable; Includes an estimate of fees 7 from the M&A and PIPE transactions, deferred underwriting fees and legal and accounting costs; Pro-forma ownership assumes no redemptions, $66.8mm PIPE and excludes impact of earn-out to existing Target equity holders, with 1mm shares vesting if the stock reaches $15 (in the first 2 years from the Closing) and 1mm shares vesting at $20 per share (in the first 3 years from the Closing), and go-forward equity incentive programs contemplated to represent approximately 22% of the pro-forma equity of the combined 8 company via stock options with customary vesting (including 15% to be issued with a $10/share exercise price pursuant to option grants made in connection with the transactions, and 7% reserved for future issuance); Excludes 965,728 shares of SPAC common stock 41 9 expected to be issued to SPAC shareholders entering into non-redemption agreements covering $86.9 million of the SPAC trust; Includes 965,728 founder shares expected to be forfeited at the closing to support the SPAC in securing non-redemption commitments

SENTI BIO Closing Remarks Senti is the pioneer in therapeutic synthetic biology Our gene circuits are biological software that are designed to power next-gen cell and gene therapies Senti’s deep differentiated allogeneic CAR-NK pipeline has the potential to address key unmet needs in cancer, including SENTI-202 for AML, SENTI-301 for HCC, and SENTI-401 for CRC Collaborations with global leaders in gene and cell therapy, Spark (Roche) and BlueRock (Bayer), indicate the broad potential of the platform Following a combination with Dynamics, Senti expects to be financially positioned to become a clinical-stage platform company delivering multiple intelligent cell and gene therapies to patients 42

Appendix 43

SCIENTIFIC ADVISORY BOARD (SAB) Senti is Founded by a World Class Team and Supported by an Advisory Board of Pioneers in Cell and Gene Therapy SENTI “SYNTHETIC BIOLOGY” ADVISORS SENTI “CLINICAL AND COMMERCIAL” ADVISORS Michael Varney, PhD Jim Collins, Ph.D. CHAIR OF R&D, SAB MEMBER AND PROFESSOR, MIT BOARD DIRECTOR AT ERASCA Scientific Co-Founder and SAB Chairperson Former Head of gRED at Genentech Michael Kalos, PhD INDEPENDENT ADVISOR AND CONSULTANT Wilson Wong, Ph.D. Fmr. Sr. Leadership at Arsenal, Janssen, Lilly PROFESSOR, BOSTON UNIV. Scientific Co-Founder Lawrence Fong, M.D. EFIM GUZIK DISTINGUISHED PROFESSOR IN CANCER BIOLOGY, UCSF Ahmad (Mo) Khalil, Ph.D. PROFESSOR, BOSTON UNIV. Michael Andreeff, M.D., PhD. Technical Advisor PROFESSOR OF MEDICINE, AND PAUL AND MARY HAAS CHAIR IN GENETICS, MD ANDERSON CANCER CENTER Martin Fussenegger, Ph.D. Robin Taylor, Ph.D., M.B.A. PROFESSOR, ETH ZURICH OWNER, TAYLOR GLOBAL BIOPHARMA CONSULTING Technical Advisor Fmr. Chief Commercial Officer at SeaGen REPRESENTATIVE PUBLICATIONS IN Genetic circuit design automation Alec A. K. Nielsen, Bryan S. Der, Jonghyeon Shin, Prashant Vaidyanathan, Vanya Paralanov, Elizabeth A. Strychalski, David Ross, Douglas Densmore and Christopher A. Voigt (March 31, 2016) Science 352 (6281), . [doi: 10.1126/science.aac7341] 44 Editor's Summary Programming circuitry for synthetic biology As synthetic biology techniques become more powerful, researchers are anticipating a future in which the design of biological circuits will be similar to the design of integrated circuits in electronics. Nielsen et al. describe what is essentially a programming language to design computational circuits in living cells. The circuits generated on plasmids expressed in Escherichia coli required careful insulation from their genetic context, but primarily functioned as specified. The circuits could, for example, regulate cellular functions in response to multiple environmental signals. Such a strategy can facilitate the development of more complex circuits by genetic engineering. Science, this issue p. 10.1126/science.aac7341 This copy is for your personal, non-commercial use only. Visit the online version of this article to access the personalization and Article Tools article tools: http://science.sciencemag.org/content/352/6281/aac7341 Permissions Obtain information about reproducing this article: http://www.sciencemag.org/about/permissions.dtl Science (print ISSN 0036-8075; online ISSN 1095-9203) is published weekly, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. Copyright 2016 by the American Association for the Advancement of Science; all rights reserved. The title Science is a registered trademark of AAAS. Downloaded from http://science.sciencemag.org/ on May 11, 2016

STARTING CELLS Multiple Potential NK Cell Sources Are Available for Clinical Application Cell Source iPSC Cord Blood Peripheral Blood Multiple clinical networks for Requires generation of GMP iPSC A few established cord blood banks Supply Chain qualified donors with extensive use in bank(s) from qualified donor(s) with experience in CAR cell therapy CAR cell therapy iPSC engineering and clone selection Well-established protocols for Well-established protocols for Genetic Engineering with extensive pre-clinical conventional genetic engineering conventional genetic engineering characterization Unclear if identical to primary NK More immature repertoire of NK Full repertoire of functional and Potency and Function cells cells mature NK cells Similar expandability to cord blood Increased expansion potential but Established methods for 1,000- NK Cell Expandability and peripheral blood smaller number of starting cells 10,000-fold expansion in 21 days Established unit operations for Well-established with similarity to GMP Process Maturity More complex, multistage process clinical process commercial CAR-T process Limited clinical experience with only Modest clinical experience with 30+ Widely used NK cell source in clinical Clinical Experience 4 clinical trials using iPSC-derived NK clinical trials using cord-derived NK trials with 200+ clinical trials using cells cells peripheral NK cells PERIPHERAL BLOOD-SOURCED NK CELLS WILL ALLOW US TO IMMEDIATELY LEVERAGE AN ESTABLISHED SUPPLY CHAIN, A MATURE GMP PROCESS, AND EXTENSIVE CLINICAL EXPERIENCE TO DEVELOP OUR NEXT-GENERATION CAR-NK CELL THERAPIES 45

CAR-NK CELL MANUFACTURING PROCESS Robust Manufacturing Process Designed to Support All Internal Programs with 1 GMP Production of Allogeneic CAR-NK Cells Engineered with Proprietary crIL-15 EXPANSION CRYOPRESERVATION PERSISTENCE Greater than 6,000-fold expansion Pre-freeze and post-thaw cells have in 21 days from frozen isolated NK similar cell viability, CAR expression, Senti’s proprietary crIL-15 enhances cells using GMP-ready process and NK cell purity NK cell killing and persistence Tumor cells alone 10,000 Unengineered NK cells NK Cell Viability CAR Expression NK Cell Purity 6,879 GPC3 CAR + wtIL-15 2 GPC3 CAR + crIL-15 100 100 60 100 1,000 2 doses/batch 1 80 164 40 60 100 0 50 40 20 10 (1) 20 0 0 0 (2) 1 0 1 2 3 4 5 6 7 0 10 20 30 Days Days of Expansion 1 Calibrated release IL-15 (crIL-15) 8 46 2 Based on 3x10 CAR-NK Cells per dose at anticipated clinical scale Fold Expansion Cell Viability (%) CAR Expression (%) CD3-/CD56+ Tumor Cell Count (ln)

TUMOR-ASSOCIATED ANTIGEN AND SAFETY ANTIGEN PARIED DISCOVERY PLATFORM Senti Developed a Powerful Tumor-Associated Antigen and Safety Antigen Paired Discovery Platform to Generate Targets for New Logic-Gated CAR-NK Candidates Tumor-Associated Antigen discovery Expression in Healthy tissue tumor cells expression of A RNA Filter for cell Curation and expression surface expression experimental data A B C 1 2 3 4 5 validation Potential Tumor- Tissues Associated Antigens Safety Antigen discovery Expression in Healthy tissue tumor cells expression of E D E F 1 2 3 4 5 Potential Safety Tissues Antigens Source: Internal data 47

TUMOR-ASSOCIATED ANTIGEN AND SAFETY ANTIGEN PARIED DISCOVERY PLATFORM SENTI-202 NOT GATE Safety Antigen Candidates Were Identified Through Senti’s Bioinformatics Approach SHORT LIST OF TARGET SAFETY ANTIGENS 1. Antigen 1 2. Antigen 2 20,216 3. Antigen 3 Protein 7,860 115 15 Coding 20,216 Genes Protein 7,860 115 15 Coding Genes On Cell High on healthy HSCs Confirmed Membrane? Low/Negative on AML Low/Negative on AML Source: Internal data 48

FLOW CYTOMETRY FOR HEALTHY HSCs AND AML LSCs: EMCN+ AND EMCN- Senti Identified a NOT GATE Safety Antigen Called EMCN That Distinguishes AML LSCs From Healthy HSCs HEALTHY HSCs (FROM HEALTHY DONOR) AML LSCs (FROM AML PATIENT) KEY TAKEAWAYS • The ‘NOT GATE’ uses EMCN as a Safety Antigen input to differentiate between healthy HSCs and AML cancer cells EMCN+ = 70.2% EMCN+ = 0% • This enables targeted killing of cancer cells while sparing healthy HSCs, thereby improving the therapeutic window EMCN EMCN 49 Source: Internal data Side Scatter (SSC) Side Scatter (SSC)

SENTI-401: LOGIC-GATED AND MULTI-ARMED CAR-NK CELLS FOR PRECISION CRC TREATMENT SENTI-401: Addressing Unmet Needs in the Treatment of Colorectal Cancer (CRC) Toolbox of SENTI’S LOGIC GATES SOLVE KEY DISEASE CHALLENGES IN CRC UNMET NEED IN CRC Gene Circuits Previous CEA therapies Challenges Senti Gene Circuit Solutions resulted in on-target/off- Logic tissue cell killing in the GI Gating 1 2 tract and lung Target heterogeneity NOT Logic Gate Targets the TAA CEA and Off-tumor tox limits Pre-treatment Post-treatment prevents toxicities against efficacy of CEA- Multi healthy lung and GI tissues targeted therapies Arming Multi Arming Disease evasion Targets multiple Suppressive tumor pathways with potent Regulator microenvironment (TME) Dial Difficult to target CEA due to off- immuno-stimulators to limits efficacy tumor expression overcome TME SENTI’S LOGIC GATES MAY MITIGATE OFF-TUMOR TOXICITY WHILE MULTI-ARMING MAY Smart Sensor OVERCOME THE SUPPRESSIVE TME TO ENHANCE CRC TREATMENT EFFICACY AND PRECISION 1 2 Parkhurst, et al. Mol Therapeutics. 2011.; Thistlethwaite FC, et al. Cancer Immunol Immunother. 2017 50

SENTI-401: CEA aCAR ANTI-TUMOR ACTIVITY + SENTI CAR-NK Cells Efficiently Kill CEA CRC cells CEA-CAR EXPRESSION CRC CANCER CELL KILLING 100 Tumor cells alone 500K 80 84.7% Unengineered NK 400K Cells SENTI CAR-NK 60 300K 200K 40 100K 20 0K 5 0 10 0 CAR expression 0 20 40 60 80 100 120 140 Elapsed time (hours) 51 Source: Internal data Relative Tumor Cell Abundance (%)

SENTI-401: VSIG2 AS SAFETY ANTIGEN FOR CEA CAR-NK Senti Discovered VSIG2 as a Safety Antigen that is Highly Expressed in Healthy Epithelial Cells, but not in CRC Tumor Cells TUMOR-ASSOCIATED ANTIGEN: CEA SAFETY ANTIGEN: VSIG2 HEALTHY COLON COLORECTAL TUMOR 52 Source: Internal data